Jeremy O'Hanlon, Gilead Sciences
“The goal of development on the team is to grow everyone into a good generalist… to make sure that those with a scientific background learn the contracting side of things and vice versa”
This week on CUTalks, we are speaking to Jeremy O’Hanlon, a Cambridge alumnus, who has worked as a corporate attorney in the life sciences and tech industries. He’s also held roles in business and corporate development in the life sciences as he currently does at Gilead Sciences in California. We spoke about M&A deals he’s worked on at Gilead, the skillset required in M&A and his insights from working with VCs.
This podcast was produced by Carl Homer, Cambridge TV.
Background - 0:57
What is corporate development - 6:16
Why do an M&A deal - 8:14
Gilead Sciences acquisitions of Immunomedics and MYR Pharmaceuticals - 11:06
Impact of pandemic on life sciences deals - 13:43
Skills required in M&A - 18:48
Venture Capital - 25:09
Dream company to acquire - 31:55